This $3 Stock Could Cure Alzheimer's and Parkinson’s

$9.1 billion… This is the combined value of the treatment market for Alzheimer’s disease and Parkinson’s disease. Editor Jeff Siegel clues investors into an opportunity that will help them get their share of that $9.1 billion market... $9.1 billion… This is the combined value of the treatment market for Alzheimer’s disease and Parkinson’s disease. Editor Jeff Siegel clues investors into an opportunity that will help them get their share of that $9.1 billion market... [Wealth Daily logo] This $3 Stock Could Cure Alzheimer's and Parkinson’s [Jeff Siegel Photo] By [Jeff Siegel]( Written Sep 28, 2020 $9.1 billion… This is the combined value of the treatment market for Alzheimer’s disease and Parkinson’s disease: two diseases that wreaked havoc on my grandmother and great-grandmother. I’m not going to lie: Watching my loved ones suffer from these horrible diseases was not easy. And in fact, one of the reasons I’m often investing in the biotech space is because I want to be a part of any potential treatment for any variety of illnesses that still have no cure. The other reason, of course, is money. Lots of money. And that’s why I’m writing to you today. Small Pill Wipes out the Deadliest Chronic Diseases Chronic diseases like alcoholism, opioid addiction, and depression can be a death sentence for millions of sufferers. Regular treatments work only 30% of the time and can take years. Now, the FDA has given the go-ahead to a small pill that wipes out these diseases with just one or two doses. And elite research institutions, like Johns Hopkins, Stanford, and Harvard, have replicated and confirmed the results. [Details here...]( $1 Billion up for Grabs I remember when my grandmother first started suffering from Parkinson’s. It wasn’t a pleasant time. You see, she was an artist. Her specialty was tropical wildlife scenes. Let’s just say there are a lot of bird paintings in my home. :) But when the Parkinson’s started kicking in, she couldn’t paint the way she used to. She struggled more and more to hold a paintbrush. Her vision suffered quite a bit, too. Eventually, her easel sat empty. It was heartbreaking. And what was so irritating was that there was nothing we could do. So when I recently read about a potential new cure for Parkinson’s, I was floored. Just think about how many people could have their lives back if such a thing really comes to fruition. And of course, as an investor, the wheels started turning too when I realized what the value of such a cure could be. This is it. Your final chance. I’ll be blunt... completely missing out on the Paydirt 2020 Summit would be a damn shame. Gerardo Del Real is one of the world’s foremost gold gurus — and his expertise leads to outrageous gains on gold. Like his 1,200% windfall on Magna Gold... Or his 2,328% return on Great Bear Resources that would have turned a $10,000 investment into over a quarter-million dollars! His Paydirt Profit Cycle never stops making gains: - 350% on Almadex Minerals - 400% on Midas Gold - 500% on Tasman Metals - 832% on Nevada Sunrise - 7,042% on Quest Rare Minerals And MANY more to come (especially in this charging bull gold market). But you’ll be the sucker left with 0% if you let this one go. Don’t let anything stop you from clicking this link right now and making a fortune on gold: [FINAL CHANCE to view the PAYDIRT 2020 SUMMIT.]( According to the Longevity Fund, a venture capital firm that invests specifically in companies seeking cures for aging-related diseases such as Parkinson’s, a single age-related indication could be worth a couple hundred billion dollars. That’s billion with a “B.” Now here’s the best part … This potential cure for Parkinson’s is being developed by a public company that [you can invest in right now](. Clinical trials are set to begin shortly, and if this thing proves to be effective, it will be a game-changer of epic proportions. Certainly for those suffering from Parkinson’s and other age-related chronic diseases, but also for investors who [get an early piece of this action](. You can read more about the science behind this potential cure [here](. And to learn more about the company, including its ticker symbol, [click here now](. To a new way of life and a new generation of wealth... [Jeff Siegel Signature] Jeff Siegel [[follow basic]@JeffSiegel on Twitter]( Jeff is the founder and managing editor of Green Chip Stocks, a private investment community that capitalizes on opportunities in alternative energy, organic food markets, legal cannabis, and socially responsible investing. He has been a featured guest on Fox, CNBC, and Bloomberg Asia, and is the author of the best-selling book, Investing in Renewable Energy: Making Money on Green Chip Stocks. For more on Jeff, go to his editor's [page](. Enjoy reading this article? [Click here]( to like it and receive similar articles to read! Browse Our Archives [Why Tesla's Battery Day Was a Major Flop]( [Three Fiber Optics Stocks Under $10]( [Peachtree Corners, Georgia: Smart City or Smokescreen?]( [GoodRx Sets IPO for Wednesday]( [America in a Nutshell]( --------------------------------------------------------------- This email was sent to {EMAIL}. It is not our intention to send email to anyone who doesn't want it. If you're not sure why you've received this e-letter, or no longer wish to receive it, you may [unsubscribe here](, and view our privacy policy and information on how to manage your subscription. To ensure that you receive future issues of Wealth Daily, please add newsletter@wealthdaily.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance. [Wealth Daily](, Copyright © 2020, [Angel Publishing LLC](. All rights reserved. 3 E Read Street Baltimore, MD 21202. The content of this site may not be redistributed without the express written consent of Angel Publishing. Individual editorials, articles and essays appearing on this site may be republished, but only with full attribution of both the author and Wealth Daily as well as a link to www.wealthdaily.com. Your privacy is important to us -- we will never rent or sell your e-mail or personal information. [View our privacy policy here.]( No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. [Wealth Daily]( does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question.